The Medical Information Working Group and the Washington Legal Foundation filed briefs in support of Amarin.
Patient advocates lobbied the FDA to approve the MS drug and Sanofi subsidiary Genzyme says their voice will be part of the consumer outreach when DTC rolls out next year.
A Credit Suisse analyst notes that the company will need to make a significant impact to meet even lowered expectations. A possible fix: more sales reps behind Belviq.
The company is supporting its professional pitch for the acne drug with a micro-targeted marketing strategy.
The new survey will study whether patients understand how efficacy is calculated and experiment with ways to make communications clearer.
AccentHealth is boosting the digital side of its business by buying MediVista Media's Everwell waiting room TV network, putting the firm's content in a thousand more doctors' offices and retail pharmacies.
The American Heart Association is trying to get us thinking about using social networks—in both the old-school, interpersonal connections sense as well as the newer electronic one—to tackle childhood obesity.
Remedy Health is looking to close the loop—and sell advertising off of it—with the launch of a service letting doctors, pharmacies and other healthcare providers send topical health content to their patients.
Google's latest data shows that the doctor-patient information divide isn't so much a divide as two parts of the same conversation.
Pfizer Oncology has recruited Desperate Housewives and West Wing star Kathryn Joosten to feature in a national education campaign titled Lung Cancer Profiles, which aims to reduce stigma and plug molecular testing of the disease as the company deepens its investment in genetically-targeted oncology therapies.
Pfizer said it plans not only to keep Lipitor consumer promotions running past the brand's expiry later this month. It also aims to put an OTC version of the megablockbuster on the market at some point.
Direct-to-consumer genetic testing is controversial in part because many medical professionals and policymakers fear that it will prompt inflated perceptions of risk in patients poorly-equipped to interpret test results. A small study suggests that, at least for those administered the test through a clinical setting, that concern may be overblown.
More than a quarter of posts on Facebook sites for people with diabetes are promotional in nature, many touting products unapproved by the FDA, according to an analysis of diabetes-focused social networks.
A survey by Yahoo! and advertising giant BBDO says advertisers need to raise their game in "owned media" like brand.com sites to woo consumers.
Asking consumers to gauge their risk for non-adherence, Merck is deploying a one-minute survey dubbed the Adherence Estimator that may be the way forward for keeping patients on-treatment.
Novo Nordisk is getting in on the boom in electronic publishing with a series of e-books available through its Cornerstones4Care patient support program.
Eli Lilly & Co. refreshed its Lilly for Better Health program with a multichannel platform and a YouTube channel.
Pfizer is piloting a mobile education campaign promoting awareness of the value of childhood vaccinations through texting.
Visitors to Crestor.com and PurplePill.com can now hit a "click to chat" button to chat with a live AstraZeneca customer service rep.
InVentiv's GSW is going after the consumer health and wellness market with an offshoot, dubbed The Well @GSW, aimed at OTC brands, consumer products and retail accounts.
Sanofi-Aventis US is expanding its social media footprint with a new "Discuss Diabetes" blog and a "WhyInsulin" YouTube channel.
Mylan's Dey Pharma launched MyEpiPen App, designed to help patients with severe allergies and their caregivers cope with episodes of anaphylaxis.
Novo Nordisk is launching an online support program for diabetes patients, dubbed Cornerstones4Care, that promises patients one-stop shopping for diabetes information and product information.
The FDA demanded that Jazz Pharmaceuticals halt dissemination of a patient brochure for Luvox CR and run corrective messages to counter inflated benefit claims and omission of risk information.
The economy might be retrenching and consumers souring, but consumer marketers are feeling more confident, according to a survey by Cegedim Dendrite which found that four in 10 expect DTC spend to increase in 2010.
Patient materials for Shire's ADHD drug Intuniv presented unsubstantiated effectiveness and superiority claims and downplayed important risk info, said the FDA's Division of Drug Marketing, Advertising and Communication.
J&J's Janssen-Cilag launched an animated patient education video aimed at showing viewers the world from the perspective of a child with ADHD and urging parents to see a doctor about behavioral problems.
Forty-four percent of women research prescribed drugs using multiple sources before filling a script, a survey found, suggesting that marketing efforts targeting Baby Boomer women, in particular, must focus less on brand awareness and more on the post-script conversation.
Eisai launched an online resource for nurses treating cancer patients. The resource, called NSider, lets nurses create customized educational packets for individual patients, which can then be emailed directly from the website to a patient, or printed out as a PDF.
Everyday Health is launching a condition-based "virtual doctor" feature for patients with chronic conditions that emphasizes compliance.
- Sunovion hires former BI exec as VP of marketing
- Five things for pharma marketers to know: Thursday, October 20, 2016
- Five things for pharma marketers to know: Monday, October 24, 2016
- Five things for pharma marketers to know: Tuesday, October 25, 2016
- Five things for pharma marketers to know: Wednesday, October 26, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy